First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
Open Access
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2015
- A hands-on practical tutorial on performing meta-analysis with StataEvidence Based Mental Health, 2014
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumorsNature Medicine, 2014
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2013
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyJournal of Clinical Oncology, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisThe Lancet, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008